Since 2019, experts believe that the time is ripe for gathering benefits from early-stage life sciences companies. This particular sector is attracting a lot of funding, with legacy VC funds also bringing in a significant amount of dollars. There are also several new players in the market, each trying to outdo each other in their targets. Corporate VC players are also active in this industry.
All this activity and funding are still present even though there are economic shifts and trade wars within major players such as China and the European Union.
The medical devices and biotechnology sectors were especially strong concerning early-stage investing in 2019. The improvements became apparent from one quarter to another, with the total investment being $2.8 million.